Major Research Foci
- Targeting of stress response pathways in gastrointestinal cancers
- Identification of distinct pathway regulations by specific p53 mutants in colorectal and pancreatic cancer
- Examination of HSP90-stabilized cytokines as regulators of the tumor microenvironment
- Exploration of disordered proteins during cancer progression and as vulnerability in cancer therapies
- 2021: Habilitation, Venia Legendi for Molecular Medicine
- since 2018: Group Leader, Principal investigator (granted by the DFG), UMG, Germany
- 2013 - 2018: Research Fellow, Molecular Oncology, UMG, Germany
- 2009 - 2012: Postdoc, Molecular Oncology, UMG, Germany
- 2008 - 2009: Postdoc, Sir William Dunn School of Pathology, University of Oxford, UK
- 2008: Ph.D. in Biology, Dept. of Neuroanatomy, UMG, Germany
- 2003: Diploma in Biology, University of Göttingen, Germany
Stipends, Awards and Prizes
- 2022: Claudia von Schilling – Medaille, auf dem Gebiet der Grundlagenforschung
- 2022: Habilitation Prize 2021, UMG, Germany
- 2021: Award Gö-VIP-26 for Nature Communications Jun 29;12(1):4019
- 2018: GZMB Award 2018, University Göttingen - postdoc prize
- 2018: Award Gö-VIP-19 for Cancer Cell 34, 298–314, Aug 13
- 2017: Else-Kröner Cancer Symposium 2017 – poster prize
- 2016 – 2018: Heidenreich von Siebold - Habilitation Stipend, Molecular Oncology, UMG, Germany
- since 2015: selected scientific member of the Else-Kröner-Fresenius Clinician Scientist Kolleg UMG
- 2012 – 2014: selected member of the Dorothea Schlözer Mentoring program, UMG, Germany
- 2012 – 2016: Dorothea Schlözer - Postdoc Stipend, Molecular Oncology, UMG, Germany
Recent publications from our group can be found here:
Selected publications of the last 5 years:
- Klemke L, Blume JP, De Oliveira T and Schulz-Heddergott R. Preparation and Cultivation of Colonic and Small Intestinal Murine Organoids including analysis of gene expression and organoid viability. Bio Protoc. 2022 Jan 20;12(2):e4298.
- Isermann T, Sener ÖC, Stender A, Klemke L, Winkler N, Neesse A, Li J, Wegwitz F, Moll UM and Schulz-Heddergott R. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity. Nature Comm. 2021 Jun 29;12(1):4019.
- Klemke L, Fehlau CF, Winkler N, Toboll F, Singh SK, Moll UM and Schulz-Heddergott R. The gain-of-function p53 R248W allele promotes migration by STAT3 deregulation in human pancreatic cancer cells. Frontiers in Oncology. 2021 Jun 11;11:642603.
- Klemke L, De Oliveira T, Witt D, Stark N, Bohnenberger H, Bucala R, Conradi L-C, Schulz-Heddergott R. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis. Feb 4;12(2):155. 2021.
- Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi L-C, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, and Moll UM. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell. 34(2):298-314. 2018.
- Alexandrova EM, Mirza S, Xu S, Schulz-Heddergott R, and Marchenko ND and Moll UM. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. Cell Death Dis. 8(3). 2017.
- Kramer D, Stark N, Schulz-Heddergott R, Ertych N, Bastians H, Edmunds S, Rossmann L, Moll UM, Concin N and Dobbelstein, MD. Strong anti-tumor synergy between DNA cross-linking and HSP90 inhibition causes massive premitotic DNA-fragmentation in ovarian cancer cells. Cell Death Differ. 24(2):300-316. 2017.
- Klusmann I, Rodewald S, Müller L, Friedrich M, Wienken M, Li Y, Schulz-Heddergott R, and Dobbelstein M. p53 activity results in DNA replication fork processivity. Cell Rep 17(7):1845-1857. 2016.
|KFO5002 “Deciphering Genome Dynamics for Subtype-specific Therapy in Pancreatic Cancer”, Scientific Project SP2||DFG, KFO 5002*||2020 - 2024|
|Targeting the tumor-driving HSF1-HSP90 system in colorectal cancer||Else Kröner Fresenius-Stiftung||2019 - 2021|
|The cytokine MIF as driver of colorectal cancer||DFG||2018 - 2022|